De Novo device
CT-132
Click Therapeutics, Inc. · Computerized Behavioral Therapy Device For Migraine (SEE, Class II) · First FDA decision Apr 11, 2025, newest Apr 11, 2025Migraine and headache
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "CT-132"
MAUDE reports
0
Brand "CT-132", since 2015
PubMed studies
7
Mentioning "CT-132"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CT-132
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- CT-132New device typeBreakthroughDe Novo
DEN240064 · Decided Apr 11, 2025 · 150 days after receipt
Device type: Computerized Behavioral Therapy Device For Migraine (SEE) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Intensive Behavioral Therapy for ObesityNational analysisReview closedCAG-00423NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational analysisReview closedCAG-00424NUpdated Sep 18, 2026
- Intensive Behavioral Therapy for ObesityNational determinationOn the books210.12Updated Dec 2, 2024
- Intensive Behavioral Therapy for Cardiovascular DiseaseNational determinationOn the books210.11Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "CT-132", any status and sponsor, newest update first.
No registered device study names "CT-132".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CT-132", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SEE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CT-132"[tiab]. The summary above synthesizes these.
- When Software Becomes Medicine: Ignoring It May Soon Be Malpractice.
Lakhan SE · Cureus · 2025Editorial
- Digital Step Therapy: A Smart Framework for Payer Adoption of Prescription Digital Therapeutics.
Lakhan SE · Cureus · 2025Editorial
- A Dose of Smart Medicine to Make America Healthy Again: A $1 Trillion Win for Health, Innovation, and the Nation.
Lakhan SE · Cureus · 2025Editorial
- Decoding FDA Labeling of Prescription Digital Therapeutics: A Cross-Sectional Regulatory Study.
Lakhan SE · Cureus · 2025
- The Composite Digital Therapeutic Index (cDTI): A Multidimensional Framework and Proof-of-Concept Application to FDA-Authorized Treatments.
Lakhan SE · Cureus · 2025
- Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention.
Lakhan SE, Petrova M, Snipes C, et al. · NPJ Digit Med · 2026
- Postmarket Safety Surveillance of FDA-Cleared Prescription Digital Therapeutics Using the Manufacturer and User Facility Device Experience (MAUDE) Database: A Pharmacovigilance Study.
Lakhan SE · Cureus · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.